Stockwinners Market Radar for June 12, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Cathie Wood's ARK Investment sold 393K shares of Tesla today

20:03 EDT Cathie Wood's ARK Investment bought 175K shares of Meta Platforms today

19:38 EDT Vision Energy announces reverse 1 for 5 stock split - Vision Energy announced that it will effect a 1-for-5 reverse stock split of its outstanding common stock. The reverse split will be effective for trading purposes as of the commencement of trading on June 13, 2023.

19:14 EDT Akoya Biosciences director buys $1.02M in common stock - In a regulatory filing, Akoya Biosciences disclosed that its director Thomas Raffin bought 203.4K shares of common stock on June 12th in a total transaction size of $1.02M. Shares of Akoya Biosciences are up 6.6% afterhours at $5.80.

19:05 EDT Microsoft's Smith says FTC suit should accelerate Activision deal process - Microsoft (MSFT) president Brad Smith said on Twitter, "Today's action by the FTC to file suit in our Activision (ATVI) case in federal court should accelerate the decision-making process. This benefits everyone. We always prefer constructive and amicable paths with governments but have confidence in our case and look forward to presenting it." Reference Link

18:37 EDT Salesforce CEO: We've increased engineering productivity 30% using generative AI - Marc Benioff is speaking on CNBC's Mad Money. "Einstein GPT Trust layer will help anonymize data. You will get productivity without giving up privacy," he noted. Salesforce is making "great strides" with telecom companies, according to Benioff.

18:19 EDT Teamsters announce opposition to Kroger-Albertsons merger - The International Brotherhood of Teamsters is formally opposing the merger of The Kroger Company (KR) and Albertsons Companies (ACI) currently under review at the Federal Trade Commission. The Teamsters represent more than 22,000 members across both companies' stores, distribution centers, and manufacturing plants nationwide. The decision to oppose the proposed merger comes after months of discussions with both Kroger and Albertsons to protect the most basic interests of Teamsters employed by the companies. "In our discussions with Kroger and Albertsons, we made clear that our members need more than vague promises about their future," said Tom Erickson, Teamsters International Vice President and Director of the Teamsters Warehouse Division. "If either company were truly sincere about protecting our members, they would agree to recognize our existing union contracts, or agree to successorship language for any of our member units sold to third parties, once the merger is complete. Instead of finding a path to ensure our members succeed in lockstep with the companies, Kroger and Albertsons apparently want to go down this road alone."

17:44 EDT WillScot Mobile Mini director sells $4.72M in common stock - In a regulatory filing, WillScot Mobile Mini disclosed that its director Jeffrey Sagansky sold 100K shares of common stock on June 8th in a total transaction size of $4.72M.

17:33 EDT Raytheon Technologies awarded $887.93M Navy contract modification - Raytheon Technologies was awarded an $887.93M firm-fixed-price modification to a previously awarded indefinite-delivery, indefinite-quantity contract. This modification increases the contract ceiling to procure F-135 propulsion system spare parts, modules, support equipment/packaging handling shipping and transportation material, and depot lay-in material in support of the F-135 propulsion system requirements for the Air Force, Marine Corps, Navy, Foreign Military Sales customers and non-Department of Defense participants. Work is expected to be completed in December 2026. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. The Naval Air Systems Command, Patuxent River, Maryland, is the contracting activity.

17:25 EDT Oracle sees FY24 cloud revenue similar to FY23 - Says experiencing unprecedented cloud services demand in FY24. Sees FY24 cloud revenue growth similar rates in FY23. Sees FY24 capital expenditures similar to FY23. Says organic revenue grew in Q4 despite closure of half billion dollar Russian business.

17:07 EDT Installed Building Products Chairman Edwards sells $14.2M in company shares - The Chairman of Installed Building Products Jeffrey Edwards disclosed in a regulatory filing that he had sold 120,000 shares of company stock at $118.24 per share between June 8 and June 9 for a total transaction amount of $14,188,908

16:58 EDT Core & Main to acquire Dangelo Co., terms not disclosed - Core & Main has entered into a definitive agreement to acquire J.W. D'Angelo Co., a full-service provider of fire protection and waterworks products with three locations in Southern California. "Dangelo Co. is regarded as an industry-leading provider of fire protection and waterworks products throughout Southern California. Their addition to Core & Main will strengthen our presence in the region and enhance the level of service we can provide to our combined customers," said Steve LeClair, chief executive officer of Core & Main. "We are excited to welcome the Dangelo Co. associates into the Core & Main family. The breadth of knowledge, dedication to outstanding customer service, and complementary product and service offering gained with this strategic acquisition will greatly bolster our presence and service capabilities in Southern California," said Brad Cowles, president of Core & Main.

16:52 EDT CapStar Bank names Christopher Tietz as Chief Banking Officer - CapStar Bank, a subsidiary of CapStar Financial, announced the appointment of Christopher G. Tietz into the newly created position of Chief Banking Officer where he will lead planning and oversight of the company's banking and specialty banking divisions.

16:46 EDT Broadcom exec Kawwas sells 1,645 common shares - In a regulatory filing, Broadcom Semi Solutions Group president Charlie Kawwas disclosed the sale of 1,645 common shares of the company on June 8 at a price of $801.33 per share.

16:41 EDT Medpace CEO sells $10.9M in common stock - In a regulatory filing, Medpace disclosed that its CEO August Troendle sold 49.3K shares of common stock on June 8th in a total transaction size of $10.9M.

16:33 EDT Chico's names David Oliver as CFO, succeeding Patrick Guido - Chico's announced that David Oliver, Senior Vice President - Finance, Controller and Chief Accounting Officer, has been appointed as Executive Vice President - CFO and Chief Accounting Officer, effective June 24. Current Executive Vice President - CFO Patrick Guido has resigned to accept a position at another company where he can be located closer to his family. Guido's last day with the company is June 23.

16:32 EDT Starton Therapeutics gets FDA notice to proceed with Lenalidomide Phase 1b trial - Starton Therapeutics provided updates on its Phase 1b STAR-LLD clinical trial of its investigational continuous delivery lenalidomide in multiple myeloma. The U.S. Food and Drug Administration notified the Company that it may proceed with the U.S.-based program in second-line transplant-ineligible patients using the combination of STAR-LLD, Velcade, and dexamethasone. This treatment paradigm will replace oral Revlimid with STAR-LLD. The planned study that follows this development will evaluate six patients for tolerability, immune biomarkers, and signals of efficacy of continuously delivered lenalidomide at the highest planned daily dose. The study is expected to accrue six patients in the United States in three to four centers over a period of 10 months and will provide readouts in the tolerability of the regimen, the impact of continuous delivery on immune function by measuring biomarkers of T-cell, NK-cell, and B-cell upregulation, and cytokine production induced by lenalidomide. It will also provide signals of efficacy in assessing response rates, duration of response, progression free survival, and changes in minimal residual disease. As part of the development plans, the FDA agreed to have a meeting to review the initial data on safety and activity from the study as an interim analysis, while patients continue treatment for efficacy endpoints. This interim review is aimed at helping develop the plans for the approval path forward with Phase 2 studies for multiple myeloma, as well as other malignancies where lenalidomide has shown activity but is not approved for the new indications planned for study. Healthwell is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

16:22 EDT AllianceBernstein reports preliminary AUM $670B as of May 31 - AllianceBernstein announced that preliminary assets under management decreased to $670B during May 2023 from $676B at the end of April. Modest firmwide net inflows were offset by market depreciation, resulting in a 1% AUM decrease during May. By channel, Institutions and Private Wealth generated net inflows, offset by Retail net outflows.

16:21 EDT Essential Properties Realty raises quarterly dividend by 1.8% to 28c per share - The dividend is payable on July 14, 2023, to stockholders of record as of the close of business on June 30, 2023.

16:20 EDT Brookfield Renewable to buy Duke Energy Renewables for $1.05B in proceeds - Brookfield Renewable announced that it has agreed to acquire Duke Energy Renewables and a 6,100 megawatt development pipeline for $1.05B in equity proceeds, approximately $265M net to Brookfield Renewable. Brookfield Renewable closed or agreed to invest up to $21B, $3.9B net to Brookfield Renewable, we have agreed to a bought deal and concurrent private placement, raising aggregate equity proceeds to Brookfield Renewable of $650M. The company said, "With the expected benefit of our growth initiatives, the majority of which we expect to come on-line over the next twelve months, and our funding approach, we believe that we remain well positioned to deliver results in-line with our track record of double digit annual FFO per unit growth."

16:19 EDT Dollar General director buys $1.32M in common stock - In a regulatory filing, Dollar General disclosed that its director Michael Calbert bought 8.5K shares of common stock on June 8th in a total transaction size of $1.32M.

16:18 EDT Cannae Holdings announces settlement of action - Cannae Holdings announced court approval of the Stipulation and Agreement of Compromise, Settlement, and Release made and entered into as of March 10, 2023, by and between the Plaintiff Oklahoma Firefighters Pension & Retirement System, the Special Litigation Committee of Cannae's Board of Directors, the company's Board of Directors and several named officers, and the company's external manager Trasimene Capital Management. Under the terms of the Settlement, among other things, the company will enter into an amended and restated management services agreement with Trasimene, providing for a new five-year term as well as: A reduction in the management fee payable to Trasimene by the company from 1.5% to 1.25% for assets under management greater than $2.5B; and a reduction in the termination fee payable to Trasimene to $20M in all circumstances, except upon a change-of-control, in which case the termination fee shall be $40M. Further, the Settlement requires an action by the company to create a Related Person Transaction Committee of its Board of Directors and adopt a Related Person Transaction Policy. The company will implement the above stated external management and corporate governance changes at its next regularly scheduled Board meeting in August 2023.

16:17 EDT Redwood Trust, Oaktree announce JV to invest in business purpose bridge loans - Redwood Trust announced the formal launch of a joint venture between Redwood and funds managed by Oaktree Capital Management, L.P. to invest in business purpose bridge loans originated by CoreVest American Finance Lender, a division of Redwood. Total equity commitment to the JV - funded 80% by Oaktree and 20% by Redwood - has the potential to finance over $1 billion of newly-originated bridge loans, inclusive of proceeds from secured financing. The vehicle has a three-year reinvestment period during which time principal repayments can be redeployed. "We are pleased to be partnering with Oaktree, a premiere global investment manager, in a joint venture that will enhance our ability to provide solutions to a broad spectrum of real estate investors at an important point in the housing cycle," said Dash Robinson, President of Redwood. "We continue to see immense opportunity for our bridge lending platform, particularly as other lenders reduce their footprint. The JV allows us to efficiently leverage our own investment capital and serve our customers in expanded ways."

16:15 EDT Chubb announces new $5B share repurchase program - Chubb announced that its Board of Directors has authorized a new $5B share repurchase program. This program is effective July 1, 2023 and has no expiration date. The company's existing share repurchase authorization will remain effective through June 30, 2023.

16:11 EDT Sandstorm Gold says 'no information' on rationale for index deletion - Sandstorm Gold is issuing a clarifying statement in response to the ICE Data Indices, LLC's recent rebalancing announcement for the NYSE Arca Gold Miners Index. On Friday June 9, 2023, the Index Manager announced that Sandstorm would be deleted from the Index effective for the rebalancing period ending June 20, 2023. "Sandstorm has no information on the rationale for the deletion and understands that the Index Manager does not release details on how its assessments are made. Based on the Index Manager's published Index criteria below, it is unclear to the Company why it would not meet the inclusion requirements, but can provide no assurance if the Index Manager will reconsider their decision and retain the company to the index".

16:08 EDT Casella Waste to acquire Consolidated Waste Services for $219M in cash - Casella Waste announced the signing of an asset purchase agreement on June 9 to acquire the assets of Consolidated Waste Services and its affiliates for a purchase price of approximately $219M in cash. The proposed acquisition, which is expected to generate annualized revenues of approximately $70M, includes two collection operations, one transfer station, one material recovery facility, one office building that can support future growth, and several satellite properties. Twin Bridges is a solid waste management company located in the greater Albany, New York market that provides residential, commercial, and industrial collection, transfer, and recycling processing services.

16:06 EDT Oracle CEO says 'revenue reached an all-time high of $50 billion in FY23' - "Oracle's revenue reached an all-time high of $50 billion in FY23," said Oracle CEO, Safra Catz. "Annual revenue growth was led by our cloud applications and infrastructure businesses which grew at a combined rate of 50% in constant currency. Our infrastructure growth rate has been accelerating-with 63% growth for the full year, and 77% growth in the fourth quarter. Our cloud applications growth rate also accelerated in FY23. So, both of our two strategic cloud businesses are getting bigger-and growing faster. That bodes well for another strong year in FY24." "Oracle's Gen2 Cloud has quickly become the number 1 choice for running Generative AI workloads," said Oracle Chairman and CTO, Larry Ellison. "Why? Because Oracle has the highest performance, lowest cost GPU cluster technology in the world. NVIDIA themselves are using our clusters, including one with more than 4,000 GPUs, for their AI infrastructure. Our GPU clusters are built using the highest-bandwidth and lowest-latency RDMA network-and scale up to 32,000 GPUs. As a result, cutting edge companies doing LLM development such as Mosaic ML, Adept AI, Cohere plus 30 other AI development companies have recently signed contracts to purchase more than $2 billion of capacity in Oracle's Gen2 Cloud."

16:06 EDT Oracle reports Q4 cloud services and license support revenue up 23% in USD - Oracle announced fiscal 2023 Q4 and full-year results. Total quarterly revenues were up 17% year-over-year in USD and up 18% in constant currency to $13.8 billion. Cloud services and license support revenues were up 23% in USD and up 25% in constant currency to $9.4 billion. Cloud license and on-premise license revenues were down 15% in USD and down 14% in constant currency to $2.2 billion. For the fourth quarter of fiscal 2023, Cerner contributed $1.5 billion to total revenues.

16:01 EDT Spruce Biosciences announces acceptance of abstract for ENDO presentation - Sruce Biosciences "announced that a submitted abstract was accepted for the 105th Annual Meeting of the Endocrine Society, or ENDO 2023, taking place June 15-18, 2023, in Chicago. In a poster presentation, the company will highlight the effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic congenital adrenal hyperplasia, or CAH."

16:00 EDT Teva settles with Kentucky on pricing fixing claims - Teva Pharmaceuticals has reached agreement with the Attorney General of Kentucky to settle the state's price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $1.407 million, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.

15:44 EDT Toast platform approved for Marriott Select service hotels in U.S., Canada - Toast (TOST) shares are higher after the company announced earlier an agreement with Marriott International (MAR) to make its Toast for Hotel Restaurants technology available to food and beverage outlets within Marriott's Select service hotels in the United States and Canada. "Forward-thinking hotel companies like Marriott want a curated food and beverage experience to be innovative, fully integrated with hotel operations, and easy to adopt for franchisees-while maintaining efficiency and scalability across brands and geographies. We're honored to offer our innovation across a variety of service models, including full-service, quick-service, poolside and in-room dining, to Marriott's Select service properties, and enhance hotels' staff and guest experience," said Aman Narang, COO and Co-Founder of Toast. In Monday afternoon trading, Toast shares have advanced $1.23, or about 6%, to $23.09.

14:59 EDT Finch Therapeutics trading halted, volatility trading pause

14:48 EDT Truist CFO says now sees full year year-over-year revenue growth of 3% - Asked about what the company is seeing in the second quarter during the Morgan Stanley U.S. Financials, Payments and CRE Conference, Truist CFO Michael Maguire stated in part: "Yes, happy to. And at another industry conference in the last week or so, our CEO, Bill Rogers made a reference to some revenue pressure in the second quarter. Just to maybe put a finer point on that, as we sit here today, our expectation is that the top line revenue is likely to decline sort of in the 3% area during the quarter, and that's largely driven by a lot of the factors you've heard us talk about so far this year. The remixing based on disintermediation of the [DDA] balances into higher yielding products, betas continue to perform a little worse than our expectations. Bill mentioned a week or so ago that on a sort of spot basis. So currently, we're at around a 43% cumulative beta. Our expectation is sort of a mid- to high 40-betas in the cards. And so that's taking a toll as well in the second quarter. And as we think about that and just as we're giving guidance around Q2, I thought we'd also just check in and give you a sense for sort of the full year outlook on revenue as well. For a lot of the same factors, be it mix, be it pricing. And also, I think as we think about building a little bit of capital, being more disciplined around RWA, focus and pricing, and we'll talk about some of the puts and takes there but a little bit more pressure on the top line for the full year as well. And so we had previously discussed sort of a 5% to 7% top line guide for the year. We're probably looking around the 3% area for the full year as well. [...] Yes, 3% revenue growth year-over-year versus 5% to 7%."

14:35 EDT Northern Trust says cost of deposits 'very, very high' due to competition - Asked at the Morgan Stanley U.S. Financials, Payments and CRE Conference if the company is seeing anything in the quarter specifically that it wants to update the market on, Northern Trust CFO Jason Tyler said in part, according to a transcript of the event: "Yes, I'll be short. There are 2 things that, as I think about the income statement and look at the forecast, jump out. One is -- and it was ironic to hear Eric talk about it an hour ago, but capital markets activity is light, foreign exchange trading is light... So trending to be less than what it was in first quarter... And -- but then I'll say also cost of deposits, very, very high, just the competition level for deposits, a lot of phone calls from clients saying, 'I want to leave my deposits there, but this is what I'm hearing from 3 other institutions.' In some instances, we're saying sounds great. But in some instances, we're saying we want to keep that in the house. And so that's -- there's going to be a pressure on NIM there. And -- but overall, volumes good, costs high."

14:12 EDT Ubisoft showcases 'Assassin's Creed VR,' 'Star Wars: Outlaws' at Forward event - At its Ubisoft Forward showcase, Ubisoft (UBSFY) made a number of game announcements, including: "Avatar: Frontiers of Pandora" will release December 7, 2023; "Just Dance 2024 Edition" will release October 24, 2023; "Tom Clancy's XDefiant" will officially launch "later this summer" following another beta test; "Captain Laserhawk: A Blood Dragon Remix," a new animated series based on "Far Cry: Blood Dragon," will be coming to Netflix (NFLX) in fall 2023; new mobile game "Tom Clancy's The Division: Resurgence" will release in Fall 2023; "Skull & Bones" will have a closed beta in August; racing game "The Crew Motorfest" will release September 14, 2023; "Assassin's Creed Nexus VR," a VR title for Meta Quest (META), was unveiled; users can register now for a closed beta of mobile title "Assassin's Creed: Codename Jade"; "Assassin's Creed Mirage" will release October 12; and the company closed the show with a gameplay trailer for "Star Wars: Outlaws," out in 2024.

13:24 EDT State Street sees Q2 total fee revenues up 4%-4.5% on q/q basis - Sees servicing fees up 3%-4% vs. previous expectations of up 1%-2%. Sees management fees slightly above the previous outlook of flat to 1% q/q. Comments taken from the Morgan Stanley US Financials, Payments & CRE Conference.

12:50 EDT FDA approves Linzess for pediatric functional constipation - The FDA announced it has approved Linzess capsules to treat functional constipation in pediatric patients 6 to 17 years of age. "Linzess is the first treatment for pediatric functional constipation. The recommended dosage in pediatric patients 6 to 17 years is 72 mcg orally once daily," the FDA stated. Reference Link

12:48 EDT Morgan Stanley's Gorman: 'Definitely mean that I will step down within a year'

12:47 EDT Morgan Stanley CEO Gorman: Unlikely bank will do more job cuts this year - Chairman and CEO James Gorman spoke at the firm's Annual U.S. Financials, Payments & Commercial Real Estate Conference.

12:32 EDT Autoliv to reduce workforce by up to 11% as part of cost reductions - In a regulatory filing earlier, Autolive announced it is accelerating its global structural cost reductions, particularly within its European operations. These actions support Autoliv's medium- and long-term financial targets and the company reiterates its full year 2023 indications. Autoliv continues to actively address its cost base to accelerate its journey towards its medium-term targets. The accelerated structural cost reduction initiatives include further optimization of the Company's geographic footprint and organizational structure, including a substantial reduction of its total direct and indirect workforce by up to 11%. Through these initiatives, Autoliv will simplify its logistics and geographic footprint and intends to close several sites in Europe. These initiatives are expected to reduce up to 2,000 indirect positions globally, or around 11% of Autoliv's total indirect workforce. Of this, up to 1,000 are expected to be in Europe. All divisions and functions will be impacted by these initiatives and the Company expects the first headcount reductions to occur in 2023. To further drive global productivity and, specifically, direct labor efficiency, the company also intends to reduce its global direct headcount. The company anticipates that this will lead to a reduction of around 6,000 positions globally, or around 11% of total direct workforce, given today's sales levels as baseline. The company expects to accrue a minor part of the total accrual in the second quarter of 2023. The initiatives are expected to be fully implemented by 2025 and to have a pay-back time of 1-2 years.

12:03 EDT Sphere Entertainment launches Sphere Studios - Sphere Entertainment announced the launch of Sphere Studios, dedicated to developing the next generation of original immersive entertainment exclusively for Sphere through proprietary technology, tools and production facilities. The first of the Studios' many immersive innovations includes Big Sky - an ultra-high resolution camera system. The studio campus in Burbank spans 68,000-square-feet of development facilities; production, editing and post-production suites; sound stages for mixing spatial audio; and camera and 3D printing labs. The campus also includes Big Dome, a 28,000-square-foot, 100-foot high custom geodesic dome with a quarter-sized version of the screen at Sphere in Las Vegas. Big Dome serves as a specialized screening, production facility and lab for content at Sphere, including Sphere Immersive Sound, haptic seats, and more that will be featured at Sphere.

12:00 EDT KeyCorp falls -7.4% - KeyCorp is down -7.4%, or -79c to $9.89.

12:00 EDT Carnival plc rises 12.7% - Carnival plc is up 12.7%, or $1.47 to $13.07.

12:00 EDT XPeng rises 14.7% - XPeng is up 14.7%, or $1.30 to $10.18.

11:31 EDT Kore Group appoint Jason Dietrich as EVP, CRO - KORE Group Holdings announced the appointment of two new leaders to help drive KORE's next phase of growth. Jason Dietrich joins the Company as Executive Vice President and Chief Revenue Officer, responsible for leading KORE's global sales and marketing teams. Mr. Dietrich joins KORE, effective immediately, and reports to President and CEO Romil Bahl. Julio Tesser joins KORE as Vice President, Latin America, and will lead KORE's efforts to expand its presence in this key market.

11:23 EDT Citizens Financial seeing higher than expected charge-offs, says CFO Woods - Comments take from the Morgan Stanley U.S. Financials, Payments & CRE Conference.

11:01 EDT Air Products' AP-X LNG technology selected for NFS project - Air Products has been selected to provide its proprietary AP-X LNG Process technology and equipment to Qatargas for the North Field South Project in Ras Laffan, the State of Qatar. It includes the supply of two new LNG process trains, adding to the four trains currently being fabricated for the North Field East LNG project, each with an additional production capacity of eight million tonnes per annum. These mega LNG trains leverage AP-X liquefaction technology, which enables significantly higher LNG production.

10:48 EDT UBS completes acquisition of Credit Suisse - UBS (UBS) has completed the acquisition of Credit Suisse (CS), the bank announced. Credit Suisse Group AG has been merged into UBS Group AG and the combined entity will operate as a consolidated banking group. Credit Suisse Group AG ADS will no longer be traded on the New York Stock Exchange. Colm Kelleher, UBS Group AG Chairman, said: "I'm pleased that we've successfully closed this crucial transaction in less than three months, bringing together two global systemically important banks for the first time. We are now one Swiss global firm and, together, we are stronger. As we start to operate the consolidated banking group, we'll continue to be guided by the best interests of all our stakeholders, including investors. Our top priority remains the same: to serve our clients with excellence." Reference Link

10:38 EDT KeyCorp sees Q2 NII down 12% vs. prior 4%-5% view

10:30 EDT KeyCorp sees NII coming in softer than expected for Q2, says CFO - Comments taken from the Morgan Stanley U.S. Financials, Payments, and CRE Conference.

10:18 EDT ABM makes strategic investment in Noodoe, terms not disclosed - Noodoe announced a key investment from ABM. ABM is investing in Noodoe through its ABM Ventures program to support growth and broader collaboration between the two companies. The investment is being announced simultaneously with ABM's unveiling of its first branded EV charging solution managed by the branded cloud-based ABM EV OS platform enabled by Noodoe. ABM's investment in Noodoe will drive forward the efforts of both companies in ushering in an era of customer-centric EV charging, creating the best possible experiences for drivers and charging service providers alike.

10:13 EDT Forza X1 receives order from OneWater Marine for 100 units of electric boats - Forza X1 (FRZA) received an initial purchase order indicating its intention to purchase 100 units of its upcoming 22-foot electric monohull boat from OneWater Marine (ONEW). As Forza gets into commercialization, the order could equate to approximately $12,000,000 in revenue for Forza.

10:03 EDT iHerb leverages Riskified's ecommerce fraud, risk intelligence platform - Riskified announced its partnership with iHerb. iHerb is leveraging Riskified's ecommerce fraud and risk intelligence platform to boost approval rates and revenues, streamline its manual review processes, and minimize fraud losses. As a result of iHerb's partnership with Riskified, only 1.5% of transactions require additional manual review, a reduction of over 90%. iHerb also expects to benefit from the liability shift of Riskified's Chargeback Guarantee product, which absorbs any chargeback costs while delivering a 99%+ approval rate.

10:00 EDT Universal Compression falls -6.4% - Universal Compression is down -6.4%, or -$1.50 to $21.78.

10:00 EDT Sandstorm Gold falls -8.9% - Sandstorm Gold is down -8.9%, or -46c to $4.72.

10:00 EDT Catalent rises 13.1% - Catalent is up 13.1%, or $5.10 to $43.91.

09:54 EDT Kuke Music establishes operating center in Wuhan, China - Kuke Music Holding announced the establishment of a new operating center in Wuhan, the capital city of Hubei Province, China. Kuke Music plans to relocate its marketing and technology departments to the Wuhan operating center. As a significant transportation hub and economic center in China, Wuhan boasts a well-developed transportation network and excellent infrastructure, which will facilitate the company's connections with various regions across the country. Additionally, Wuhan offers relatively reasonable operating costs, abundant talent resources, and high-quality educational institutions, providing Kuke Music with comprehensive resources that are economically beneficial and conducive to improving operational efficiency.

09:47 EDT Sandstorm Gold falls -6.7% - Sandstorm Gold is down -6.7%, or -34c to $4.83.

09:47 EDT SentinelOne rises 7.6% - SentinelOne is up 7.6%, or $1.11 to $15.66.

09:47 EDT XPeng rises 9.5% - XPeng is up 9.5%, or 84c to $9.71.

09:37 EDT Carvana up fractionally as short-seller Kerrisdale calls stock 'worthless' - Shares of Carvana retreated in pre-market trading after Kerrisdale Capital published a report regarding its short thesis on the stock, but the shares are fractionally higher in early trading following the report's publication. In the report published on its site, the firm says in part: "We are short shares of Carvana Co. (CVNA), a $4B market cap online platform for buying and selling used cars. Originally hyped up as an innovative disruptor, Carvana is now recognized to be just a poorly run auto retailer struggling under the challenges of a severe industry downturn and the unsustainable burden of $6.5B in debt." Shares have risen 165% in only a month on "misguided optimism for profits that amount to little more than buffing the paint job on a totaled car," contends the firm, which adds that "Carvana shares are worthless." Kerrisdale concludes its report by stating: "Carvana should be valued like any other publicly traded auto retailer, and specifically one that is poorly capitalized and more cyclical due to a lack of diversification and subprime exposure. We view the equity as a zero and investing at current levels is a worse deal than buying a clunker from a slick used car salesman." Reference Link

09:35 EDT Avalon Acquisition Inc trading halted, volatility trading pause

09:29 EDT Carvana down 4% in pre-market following Kerrisdale short call - Shares of Carvana are down 67c, or 4%, to $18.40 in pre-market following the short-seller's report.

09:23 EDT Lexaria Bioscience appoints Mike Shankman as outsourced CFO - Effective immediately, Mike Shankman has been appointed as outsourced CFO. Chris Bunka will also assume the role of principal financial officer at this time.

09:21 EDT Blackstone announces majority investment in New Tradition - Blackstone announced that funds managed by Blackstone Tactical Opportunities have acquired a majority stake in New Tradition Media, which it calls "a leading out-of-home media operator with assets across the nation's largest markets." Terms of the transaction were not disclosed. Evan Richheimer, Co-Founder and CEO of New Tradition, said: "We're thrilled to partner with Blackstone, whose track record of scaling founder-led businesses and significant real estate expertise, will enable New Tradition to accelerate the expansion of our footprint and continue to provide cutting edge out-of-home advertising solutions to new and existing clients." John Watson, Managing Director, and Kern Vohra, Senior Associate, at Blackstone, added: "Technological advancements in digital signage are transforming the way consumers engage with the physical advertising industry. Evan, Bret, Vince and Lu are respected leaders in this evolving market and have created iconic advertising activations across the country on behalf of their customers. We're excited to leverage Blackstone's scale, resources and relationships to support New Tradition's continued expansion and innovation."

09:19 EDT Via Renewables appoints Stephen Kennedy to board of directors - Via Renewables announced that Stephen Kennedy has been appointed to the Company's Board of Directors, effective June 7, 2023, as an independent director. He will serve as a Class II director and will join the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. Additionally, the Company announced the departure of Nick Evans from its Board of Directors, effective June 9, 2023. Steve Kennedy began his role as Founder & Senior Advisor - Energy Group for Amegy Bank in 2022.

09:17 EDT Atossa Therapeutics completes PK run-in cohort enrollment in Phase 2 trial - Atossa Therapeutics announces that the pharmacokinetic run-in cohort of the Phase 2 EVANGELINE study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa's patented Selective Estrogen Receptor Modulator, (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive/ Human Epidermal Growth Factor Receptor 2 negative breast cancer. The PK run-in cohort consists of six patients, all of whom will be treated with (Z)-endoxifen at 40mg/day for four weeks. The goal of the PK run-in cohort is to determine if the 40mg dose delivers steady-state plasma concentrations between 500 - 1000 ng/mL, which are optimal to target PKCbeta1 inhibition and enhance (Z)-endoxifen's antitumor mechanism of action. Once the optimal dose of (Z)-endoxifen is determined, the Treatment Cohort will commence. Participants in the treatment cohort will receive neoadjuvant treatment for up to six months, followed by surgery. The study is expected to enroll approximately 175 patients at up to 25 sites across the United States.

09:14 EDT Interactive Strength secures $15M credit facility - Interactive Strength announces that on June 6th the Company signed a note purchase agreement to issue senior secured notes with gross proceeds to the Company of up to $15.0 million. The lead investor has committed to purchase at least $7.5 million of the Notes and the Notes have a two-year maturity, at 10.0% interest per annum, and with a 5.0% original issuance discount, representing a total cost of debt of 12.5% over the term of the Notes.

09:11 EDT Fortinet announces new product, service additions to FortiFlex program - Fortinet announced new product and service additions to its FortiFlex program, delivering even more flexible licensing options to customers. FortiFlex already includes a complete suite of virtualized solutions for protecting cloud and virtual data center deployments and now supports services for physical FortiGate next-generation firewall appliances. FortiFlex is also available beginning today via a private offer in AWS Marketplace as an additional purchasing option.

09:08 EDT Digerati Technologies postpones special meeting of shareholders - Digerati Technologies filed a definitive proxy statement with respect to a special meeting of its stockholders to be held on Thursday, May 25, 2023 at 11:00 a.m. EDT to vote on, among other things, a proposal to adopt and approve that certain Business Combination Agreement by and among Digerati, Minority Equality Opportunities Acquisition Inc., a Delaware corporation and MEOA Merger Sub, Inc., and the business combination contemplated thereby. On May 24, 2023, Digerati determined to postpone the Special Meeting until Friday, May 26, 2023, then on May 25, 2023 and May 30, 2023 the Company announced further postponements. On June 12, 2023, Digerati determined to further postpone the Special Meeting until a date, on or prior to June 30, 2023. At such time as the date and time of the Special Meeting is decided, Digerati shall issue a press release and file a Current Report on Form 8-K providing such information to its stockholders. Digerati shall endeavor to publicly disclose the date and time not less than forty-eight hours in advance of the Special Meeting.

09:07 EDT Verses announces C$6.8M proceeds from warrant, option exercises - VERSES AI received an additional CDN $6,778,062 from the exercise of 6,534,385 Class A subordinate voting share purchase warrants and 310,000 stock options. A total of 7,606,734 Class A subordinate voting share purchase warrants, 943,777 broker warrants and 960,000 stock options have been exercised since March 13th, 2023, for total gross proceeds of CDN $9,264,362.

09:06 EDT LPL Financial: Van Buren Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Rodney Van Buren and Whitney Colton have joined LPL Financial's broker-dealer, RIA and custodial platforms. The advisors reported having served approximately $200 million in advisory, brokerage and retirement plan assets and join from VALIC Financial Advisors, Inc., the broker-dealer for AIG Retirement Services. With this move, the team has launched an independent practice, Van Buren Wealth Management, based in Melbourne, Fla. They are joined by client relations and executive support staff members Karen Savage and Nicole Wilbert, who share a passion for helping clients and their families.

09:04 EDT SomaLogic, Citogen partner to expand authorized site program in Europe - SomaLogic announced their collaboration with Citogen, the Longwood Group's customer services and support unit, to establish the company's first authorized site in Spain. As part of the agreement, Citogen will offer the 7,000-plex SomaScan Assay and provide SomaScan data to their customers in Southern Europe supporting biological research across an array of disciplines including clinical research, population health studies and nutrigenomics.

09:02 EDT Heron Therapeutics names William Forbes, Pharm.D. as Chief Development Officer - Heron Therapeutics announced the appointment of William Forbes, Pharm.D., as Executive Vice President, Chief Development Officer. In addition, Kimberly Manhard, Heron's Executive Vice President, Drug Development, has resigned from her position. Dr. Forbes joins Heron's management team and will be responsible for leading clinical and product development for Heron's acute care and oncology care franchises.

09:01 EDT Precision Optics names Wayne Coll as CFO, effective June 12 - Precision Optics announced the appointment of Wayne Coll as CCFO, effective June 12. With a career spanning more than 30 years, Coll is an experienced public company CFO, including experience at publicly-held National Dentex Corporation and Micron Solutions, and privately-held Flowonix Medical Incorporated, Keystone Dental, Modern Dental Laboratory USA and Pluromed. Coll replaces Interim CFO Kevin Dahill. Coll joins Precision Optics most recently from Flowonix Medical Incorporated where he served as CFO since July 2021.

08:58 EDT Canopy Growth provides update on management cease trade order - Canopy Growth is providing this bi-weekly update on the status of the management cease trade order granted on June 2, 2023 by its principal regulator, the Ontario Securities Commission under National Policy 12-203 - Management Cease Trade Orders, following the company's announcement on May 26, 2023 that the company has initiated an internal review of the financial reporting matters related to BioSteel Sports Nutrition and has determined that it will need to restate its (i) audited consolidated financial statements for the fiscal year ended March 31, 2022, included in the company's Annual Report on Form 10-K for the fiscal year ended March 31, 2022 and (ii) unaudited consolidated financial statements for the quarterly periods ended June 30, 2022, September 30, 2022 and December 31, 2022, included in the Corporation's Quarterly Reports on Form 10-Q for such quarterly periods. The company reports that: (i) there are no changes to the information contained in the Default Announcement that would reasonably be expected to be material to an investor; (ii) the company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports until the Restated Financial Statements are filed, each of which will be issued in the form of a press release; (iii) there has not been any other specified default by the company under NP 12-203, and, except as set forth below, no such other default is anticipated; (iv) the company is not subject to any insolvency proceedings; and (v) there is no material information concerning the affairs of the company that has not been generally disclosed. The company continues to work with its auditors to complete the Restated Financial Statements further to the company's recent filing of Form 12b-25 with the U.S. SEC. While the company is continuing to work diligently to complete the BioSteel Review and the Restated Financial Statements it will not report its Annual Report on Form 10-K for the fiscal year ended March 31, 2023 on or before the expiration of the 15 calendar day extension provided by Rule 12b-25(b) but expects to file on or before June 23, 2023.

08:56 EDT Siyata says Minnesota Coaches takes delivery of SD7 Handsets, VK7 Vehicle Kits - Siyata Mobile announced that Minnesota Coaches has taken delivery of its first Siyata SD7 Handsets and VK7 Vehicle Kits. The devices have been installed in a fleet of motorcoaches operating from seven different locations in the upper Midwest. Minnesota Coaches is deploying its SD7 and VK7 devices to replace existing land mobile radio devices. Siyata equipment is now operating in nearly 90 of Minnesota Coaches' fleet vehicles. When fully implemented, the Company expects Minnesota Coaches to deploy SD7 and VK7 in the balance of their fleet of over 900 vehicles.

08:54 EDT Meta Materials appoints Jeff Dahn to Scientific Advisory Board - Meta Materials announced that Prof. Jeff Dahn is joining its Scientific Advisory Board effective June 15, 2023. Prof. Dahn is a pioneering researcher and developer of lithium-ion battery technology and leads a large research group at Dalhousie University. Prof. Dahn's expertise will bolster META's endeavors to drive innovation of NCORE and NPORE battery materials, enabling the development of new lithium-ion batteries that are safer, more efficient, and environmentally sustainable. Prof. Dahn held the position of NSERC/Tesla Canada Industrial Research Chair with Dalhousie University from 2016 to 2021. He is now Principal Investigator of the NSERC/Dalhousie/Tesla Canada Alliance Grant which will run until at least 2026.

08:52 EDT SetPoint Medical names Cutera CFO Rohan Seth as new CFO - SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the appointment of Rohan Seth as CFO. Prior to SetPoint Medical, Seth served as the CFO at Cutera (CUTR), a leading provider of aesthetic and dermatology solutions.

08:51 EDT Ford announces $2B investment in Cologne Electric Vehicle Center - Ford opened the Cologne Electric Vehicle Center, a production facility in Germany that will build Ford's new generation of electric passenger vehicles for millions of European customers. Ford has transformed its plant in Niehl, Cologne - first founded in 1930 - as part of a $2B investment. The 125-hectare site is equipped with a brand-new production line, battery assembly and state-of-the-art tooling and automation, enabling an annual production capacity of 250,000+ EVs. Ford recently unveiled its fourth EV globally, the electric Explorer, which will be the first electric vehicle to be produced in Cologne, followed by a second electric vehicle, a sports crossover. The Cologne EV Center will be Ford's first carbon neutral assembly plant to open globally and supports the company's commitment to reach carbon neutrality across its entire European footprint of facilities, logistics and direct suppliers by 2035.

08:47 EDT NeuroOne Medical submits 510(k) application for OneRF ablation system - NeuroOne Medical announced its submission of a 510(k) application to the U.S. Food and Drug Administration for its OneRF Ablation System. This technology uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to a proprietary radio frequency generator. If cleared by the FDA, NeuroOne's OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery. As the Company's first therapeutic device, OneRF is a combination system that includes both diagnostic and therapeutic capabilities. The system utilizes a customized RF generator with real-time temperature monitoring capabilities, allowing clinicians to have greater control over temperature management during the ablation. Designed to both record brain activity and ablate nervous tissue using the same electrode, the system is designed to offer the potential for a safer clinical option for patients as well as lower costs by reducing the number of invasive procedures and hospital stays for patients. NeuroOne estimates the current brain ablation market to be at least $100M worldwide and growing rapidly, with the potential to grow multiple fold based on large addressable patient populations with unmet clinical needs. NeuroOne anticipates receiving initial feedback from the FDA no later than August 7th, 2023.

08:45 EDT Quisitive Technology adds MDR to security services portfolio - Quisitive Technology is adding 24x7x365 Managed Detection and Response capabilities to its services portfolio, as an integrated service within its Spyglass Security solution and Azure Management Services solution. Quisitive has selected CRITICALSTART a leading partner in Microsoft Managed Extended Detection and Response security services program, as well as a member of the Microsoft Intelligent Security Association, as a partner to augment Quisitive's portfolio of enterprise security and compliance solutions.

08:42 EDT Cellectar Biosciences expects topline data from WM CLOVER-WaM trial in 2H23 - Cellectar Biosciences provided an update for its iopofosine I 131 clinical program and guidance related to its Waldenstrom's macroglobulinemia CLOVER-WaM pivotal trial, as well as preclinical advancements to its proprietary phospholipid ether drug conjugate platform. The company now expects to release top-line data from the WM CLOVER-WaM trial in the second half of 2023 and assuming NDA approval, remains on target for a 2024 product launch. Cellectar experienced delays with trial start-up activities, such as site contracting and country regulatory responses, which slowed the initial pace of site initiations resulting in lower-than-expected patient enrollment. The company now has all 49 sites up and running and patient enrollment rates have accelerated. As has been previously reported, and in agreement with the FDA, WM CLOVER-WaM is a single arm, open label trial with a target enrollment of 50 patients. With the support of a $2 million grant from the National Institute of Health's National Cancer Institute the company plans to initiate a Phase 1b study in pediatric high-grade gliomas in the third quarter of 2023. The study objective is to identify the recommended iopofosine I 131 Phase 2 dose in pHGG patients. The NCI grant was in part driven by the Phase 1a trial data demonstrating a near tripling of the progression free survival typically observed in relapsed/refractory patients. Iopofosine I 131's ability to cross the blood-brain barrier and recently demonstrated activity in central nervous system lymphoma provides further rationale for treatment of WM patients with CNSL involvement, also known as Bing-Neel syndrome. Based upon achieving a complete response in a CNSL patient treated as part of its Phase 2a trial, the company expanded the CNSL cohort to further evaluate iopofosine I 131 in this indication. Currently, there are no approved therapies available to CNSL patients. Iopofosine I 131 has been evaluated in over 125 multiple myeloma patients including triple class refractory, quad/penta refractory, high-risk and post-BCMA patients with response rates ranging from 40 to 62%. The company's recently published post BCMA response rate of 50% prompted expansion of this cohort in our ongoing Phase 2a trial. The company's COO, Jarrod Longcor, will deliver an oral presentation of iopofosine I 131 in multiple myeloma at the Society of Nuclear Medicine and Molecular Imaging Annual Conference. The presentation is on June 26th. Development of the company's phospholipid ether cancer targeting platform continues to demonstrate its broad utility to provide targeted intracellular delivery of multiple cancer treatment modalities. Preclinical data recently presented at several conferences demonstrate the broad utility of the platform, including: multiple alpha-emitter radiotherapeutic programs targeting solid tumors; the activity of multiple cytotoxic small molecule payloads in triple negative breast cancer mouse models including eradication of the tumors with no subsequent regrowth; the successful delivery, uptake, and gene knockdown in a mouse model of pancreatic cancer with siRNA-phospholipid ether when given intravenously; and, the conjugation and use of peptides against intracellular targets where small molecules may not be effective.

08:38 EDT Safe & Green announces purchase of Waldron Manufacturing Facility - Safe & Green Holdings that SG Echo a wholly owned subsidiary of the Company, has purchased the Waldron manufacturing facility in Durant, Oklahoma, which SG Echo has been leasing. The Waldron manufacturing facility, which has been under lease since November 2021, came with an option to purchase the facility for $1M. Subsequent to the original lease agreement, the Company funded approximately $2.5M of upgrades to the facility. As a result, the facility was recently appraised for $5.2 million, which is approximately $1.7 million over the Company's all-in investment. In turn, SG Echo, secured a $1.75M commercial mortgage on Waldron and a $1.5M financing agreement which funded the purchase of the facility as well as provided it with additional working capital.

08:38 EDT Lumen collaborates with Google, Microsoft on interconnection ecosystem - Lumen (LUMN) announced a new network interconnection ecosystem called ExaSwitch, created in collaboration with Google (GOOG, GOOGL) and Microsoft (MSFT). This platform empowers organizations with high bandwidth needs to route their traffic dynamically and quickly between networks, and without third-party intervention. This ExaSwitch project was created by the initial participants to route traffic between large internet and cloud networks. Early adopters include Lumen, Google Cloud, Microsoft Azure and an additional large cloud provider. The ExaSwitch ecosystem will continue to strengthen as additional participants join, making it easier to automate, scale and manage capacity between the members.

08:36 EDT Huntington pausing buybacks is 'right plan,' says CFO

08:35 EDT Huntington Bancshares focused on CRE, small business portfolio, says CFO

08:35 EDT ABVC BioPharma enrolls first subject for ADHD Phase II Part 2 study - ABVC BioPharma announced that the first subject was enrolled at University of California San Francisco Medical Center on June 9, 2023. The UCSF site, led by Professor Keith McBurnett, PhD, Psychiatry UCSF Weill Institute for Neurosciences, joins the five Taiwan sites that have begun patient enrollment for the Company's ADHD Phase II Part 2 clinical study. The study entitled "A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder, Part II" is a randomized, double-blind, placebo-controlled study involving a total of approximately one hundred patients in the United States and Taiwan. A total of fifty-three (53) participants have been enrolled and forty-three have completed the eight-week study thus far. The Phase II Part 2 study is a continuation of the Phase II Part 1 study of ABV-1505 which was completed successfully by achieving the protocol specified primary end points at UCSF and accepted by the US Food & Drug Administration in October of 2020.

08:33 EDT Sabre, Aeromexico launch NDC content to Sabre-connected travel agents - Sabre and Aeromexico announced that the carrier's NDC content is now available through Sabre's global distribution system. Aeromexico is rolling out its NDC offers in waves, starting in Mexico this month. The airline's content is now available through the Sabre Offer and Order APIs, agency booking solution Sabre Red 360 and Sabre's online booking tool, GetThere for travel agencies based in Mexico. Thousands of Sabre-connected agencies in more than 150 countries around the world are already shopping, booking, and servicing NDC content through the Sabre GDS.

08:33 EDT Lantern Pharma announces FDA clearance for LP-184 IND - Lantern Pharma announced that the FDA has cleared the investigational new drug, or IND, application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system, or CNS, cancers. The first-in-human Phase 1A trial for LP-184 is anticipated to launch and dose its first patient during the current quarter.

08:32 EDT Phathom announces FDA acceptance of NDA resubmission for vonoprazan - Phathom Pharmaceuticals announced that the U.S. Food and Drug Administration has acknowledged that its New Drug Application resubmission for vonoprazan, a novel potassium-competitive acid blocker, for the treatment of Erosive GERD constitutes a complete response to the February 2023 complete response letter. The FDA has classified this as a Class 2 resubmission and assigned a Prescription Drug User Fee Act goal date of November 17, 2023. The NDA resubmission, which was submitted in response to the CRL issued by the FDA in February 2023, contained three months of stability data of reformulated vonoprazan tablets to support the commercial shelf life of vonoprazan. Phathom will continue to provide additional stability data during the regulatory review as previously agreed with FDA as part of this resubmission.

08:30 EDT B2Gold announces ISS recommends shareholders vote for all proposed items - B2Gold is pleased to announce the support of ISS, who has recommended that shareholders vote FOR all proposed items to be considered at the upcoming Meeting. .

08:26 EDT Gorilla enters binding terms to acquire Bacom Internetwork - Gorilla Technology Group announced that it agreed to binding terms to acquire Bacom Internetwork, a distributor and systems integrator of Smart City Infrastructure solutions in Thailand. The planned transaction is expected to close by the end of September and is subject to confirmatory due diligence, finalizing transaction documentation, and obtaining necessary local regulatory approvals. Following the completion of the transaction, Bacom will become a wholly-owned subsidiary of Gorilla. The acquisition is a significant milestone in Gorilla's goal to establish a globally dominant position for Smart and Safe City solutions. With Bacom's record of accomplishment, as a leading provider in Thailand, there is exceptional potential for further expansion. Based on internal analysis and current market projections, Gorilla believes that Bacom could achieve a compounded annual growth rate of over 50% over the next three years.

08:24 EDT Shoals Technologies, Blattner Company enter 10 GW master supply agreement - Shoals Technologies announced the signing of a Master Supply Agreement with Blattner Company, to deliver 10 GW of its Big Lead Assembly and systems solutions over the next two years. Deliveries for projects have begun, with an expected completion by the second quarter of 2025.

08:23 EDT Microchip announces 5071B cesium atomic clock - To provide multiple industries-including telecommunications, data centers, metrology, aviation and defense-with a long-term and precise timing and frequency solution, Microchip Technology announces the 5071B cesium atomic clock that can perform autonomous time keeping for months in the event of GNSS denials. Microchip's 5071B is the next-generation commercial cesium clock to the existing 5071A, which has been the primary contributor to international time for more than three decades. The 5071B is available in a three-unit height 19-inch rackmount enclosure, providing a compact product to work in environments where it can be easily transported and secured versus a larger alternative designed specifically for laboratory environments.

08:21 EDT China Medical System receives NMPA approval for Diazepam Nasal Spray NDA - On June 12, China Medical System Holdings announced that on June 7 2023, the New Drug Application of Diazepam Nasal Spray received approval from the National Medical Products Administration of China. The Product is the first diazepam nasal spray in China, and it is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older. The results of the Product's US related clinical trial showed that 87% of seizure cluster episodes used a single dose of the Product over a 24-hour period. A post hoc analysis of these data showed the Product had a rapid onset of action with the median time from administration of the Product to seizure cessation of 4 minutes. Further analyses showed using the Product as intermittent rescue therapy significantly improves the quality of life of epileptic patients and may reflect a beneficial effect in increasing time between seizure clusters. In 2020, the Product was approved for marketing in the United States of America.

08:18 EDT Arqit Quantum, DETASAD enter strategic teaming agreement - Arqit Quantum and DETASAD announced a strategic teaming agreement to collaborate on creating sovereign security solutions and services. The partnership will harness the power of Arqit's QuantumCloud Symmetric Key Agreement Platform and DETASAD's data sovereign cloud, cyber security and smart infrastructure solutions and services to provide unparalleled security solutions for DETASAD clients' infrastructure, communications, data, devices, sensors and any type of networks across the MENA region. This strategic partnership delivers sovereign encryption through DETASAD, leveraging its extensive network infrastructure, technical expertise, and market reach, to Governments, Critical Infrastructure and Commercial Enterprises. This collaboration will enable DETASAD to offer its customers in the Kingdom of Saudi Arabia, and the wider region, unparalleled levels of security and privacy, guarding against current and future cyber threats.

08:17 EDT BigBear.ai gets 6-month extension from Army for $8.5M GFIM system work - BigBear.ai announced that it has received a 6-month extension from the U.S. Army as the prime contractor for continuing work on the Global Force Information Management GFIM system, in a 6-month contract valued at just over $8.5M. The extension builds on BigBear.ai's previous work in Phase 1 and Phase 2. Under the terms of the single-source contract, BigBear.ai as the prime contractor will partner with Deloitte, Appian, and Ignite IT in continuing to build the enterprise-wide intelligent automation platform, providing the U.S. Army with a holistic view of its global force structure. As part of the work completed in Phase 2, foundational force design, registration, and accounting capabilities were developed and user validation tested by users across the Total U.S. Army. During the extension the BigBear.ai team will be charged with migrating the Prototype into U.S. Army's cARMY cloud, aligned with the U.S. Army's Cloud Plan 2022. BigBear.ai and the teams' solution helps the U.S. Army address Secretary of the Army Christine Wormuth's objective to embrace emerging technologies and become more data-centric.

08:15 EDT American Lithium completes strategic investment in Surge Battery Metals - American Lithium has completed its strategic investment in Surge Battery Metals. The Investment of C$5,360,000 represents the full commitment from American Lithium and is the cornerstone investment in the recently announced Surge private placement. American Lithium now holds approximately 9.7% of the total issued and outstanding shares of Surge. In connection with the Investment, American Lithium has been issued 13,400,000 units of Surge at a price of $0.40 per Unit with each Unit being comprised of one common share and one share purchase warrant. Each Warrant is exercisable for a period of three years from the date of issuance at a price of $0.55 per share. The securities comprising the Units and any shares underlying the Warrants may not be sold until October 10, 2023. As part of its investment, American Lithium has the right to elect a Director to the Surge Board of Directors and has elected Ted O'Connor, its Executive Vice President, to represent the Company and he has been appointed with immediate effect. The Company has also entered into an Advisory Agreement with Surge pursuant to which it will provide technical advice to Surge in relation to the ongoing exploration and development of the Nevada North Lithium Project and will be provided all relevant data.

08:12 EDT Myriad Genetics enters research collaboration with MD Anderson - Myriad Genetics announced an agreement with The University of Texas MD Anderson Cancer Center to support research focused on metastatic renal cell carcinoma treatment selection and response. The project will use Myriad's minimal residual disease testing platform, a tumor-informed high-definition assay that detects circulating tumor DNA. Myriad is working together with Chad Tang, MD and Pavlos Msaouel, MD, PhD at MD Anderson. The research team will investigate the use of Myriad's MRD testing platform as a non-invasive tool to inform treatment selection, surveillance, and radiotherapy treatment response in individuals with metastatic renal cell carcinoma. There currently is a lack of non-invasive testing platforms available for RCC, and MRD tests based on exome sequencing of the tumor may not track enough variants to be sufficiently sensitive. The goal of this research is to determine if patients with RCC will benefit from a comprehensive genome-wide approach to MRD with this platform. Myriad's MRD test is available for use in research studies pursued jointly by Myriad and academic or pharmaceutical investigators. It can be used to monitor ctDNA levels during both treatment and surveillance following diagnosis.

08:11 EDT Worksport relocates corporate HQ to West Seneca, New York - Worksport announces the strategic relocation of its corporate headquarters from Ontario, Canada to its U.S.-based manufacturing facility in West Seneca, New York. This decisive move is perfectly timed as Worksport ramps up to initiate its production cycle within the next eight weeks. This strategic shift of the company's HQ to be onsite with its new 220,000 square-foot facility in West Seneca, NY, aligns with the company's mission to significantly turbocharge operations, facilitate enhanced process flow, and foster a solid working community and culture of high productivity. In anticipation of the company's finalization of its assembly line setup, it has recently bolstered its talent pool with a second job fair, securing a workforce poised to drive efficient manufacturing operations. The onset of production will represent Worksport's entry into an exciting new phase of its growth plan as the team pivots from production setup to a strong emphasis on revenue acceleration. The company's innovative truck bed covers have already won approval from a national U.S. customer and reseller of automotive aftermarket accessories after a recent sample inspection. Management expects it to be a robust revenue generator. Additional details will be shared as they become finalized. As the year progresses, investors can look forward to the anticipated production launch of the SOLIS solar cover, a ground-breaking initiative contingent upon the progress of the company's proprietary COR battery system.

08:09 EDT Horizon publishes new analysis from UPLIZNA N-MOmentum clinical trial - Horizon Therapeutics announced the publication of a new analysis from the N-MOmentum clinical trial of UPLIZNA demonstrating the utility of a robust adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder, NMOSD, through more accurate and consistent assessment of disease-related attacks. These findings are published in the Multiple Sclerosis Journal. NMOSD is characterized by recurrent disabling attacks, which often lead to permanent disability. Properly defining NMOSD attacks is essential to inform treatment decisions, yet there are no universally accepted criteria for accurate and objective diagnosis of NMOSD attacks. The N-MOmentum pivotal trial, which demonstrated UPLIZNA reduced the risk of attacks associated with the disease, introduced a new approach for a"Together with well-defined review criteria and biomarker analysis, this robust adjudication process could serve as the basis for consistent attack evaluations in future studies and real-world care," said Kristina Patterson, M.D., Ph.D., senior medical director, neuroimmunology medical affairs, Horizon. "Importantly, the accurate picture of disease-related attack events seen in this analysis further reinforces the efficacy of UPLIZNA in reducing these attacks and improving outcomes for people with NMOSD." ttack analysis. Attacks were evaluated by an adjudication committee . The approach was revised based on guidance from the U.S. Food and Drug Administration FDA. The process evaluated 18 predefined criteria . Domain-specific MRI review was performed in scenarios where the clinical findings were indeterminant...

08:08 EDT Cyclo Therapeutics announces patent allowance from EPO - Cyclo Therapeutics announced that the company received a Communication from the European Patent Office, or EPO, regarding Cyclo Therapeutics' European Patent Application No.19805439.7 titled, "Methods for Treating Alzheimer's Disease." The EPO Communication stated that "[t]he newly filed claims are considered to be allowable" and that "[t]he applicant is therefore requested to bring the description into conformity with these claims."

08:07 EDT Arqit Quantum, DETASAD announce strategic teaming agreement - Arqit Quantum and DETASAD, a provider of telecommunications and ICT services in the Kingdom of Saudi Arabia, announced a strategic teaming agreement to collaborate on creating sovereign security solutions and services. The partnership will harness the power of Arqit's QuantumCloud Symmetric Key Agreement Platform and DETASAD's data sovereign cloud, cyber security and smart infrastructure solutions and services to provide unparalleled security solutions for DETASAD clients' infrastructure, communications, data, devices, sensors and any type of networks across the MENA region.

08:05 EDT Geron announces new data from IMerge - Geron announced new data and analyses from IMerge Phase 3 reporting robust durability of transfusion independence, or TI, evidence for disease-modifying activity and favorable fatigue patient-reported outcomes, or PRO, in lower risk myelodysplastic syndromes, or MDS, patients treated with the company's first-in-class telomerase inhibitor, imetelstat, vs. placebo. The data and analyses were presented at the European Hematology Association annual meeting, which took place from June 8-11, 2023 in Frankfurt, Germany and virtually. Top-line results from the primary analysis of IMerge Phase 3 presented earlier this month at the 2023 American Society of Hematology, or ASCO, annual meeting were also covered in the EHA presentation, including the primary endpoint of eight-week transfusion independence and key secondary endpoint of 24-week TI were met with high statistical significance for imetelstat-treated patients vs. placebo. Further, mean hemoglobin levels in imetelstat-treated patients increased significantly over time compared to placebo patients. In addition to these results, the EHA presentation also provided new data and analyses highlighting clinically meaningful and durable TI for imetelstat-treated patients vs. placebo. As of a January 2023 data cut-off, 17.8% of imetelstat-treated patients vs. 1.7% of placebo-treated patients achieved 1-year TI, representing 63.6% of 24-week TI imetelstat responders. Two new analyses presented at EHA on TI responses by subgroups underscored the breadth of potential effect of imetelstat vs. placebo.

08:04 EDT Shengfeng Development purchases 16 electric heavy-duty trucks - Shengfeng Development announced it has purchased 16 electric heavy-duty trucks with an aggregate value of $1.55M. The company plans to have at least 10% of its future purchases of heavy-duty trucks to be electric heavy-duty trucks. In addition to the purchase of electric heavy-duty trucks, the company will also build battery swapping stations in its regional sorting centers, cloud-based order fulfillment centers, and service outlets, to better serve its electric vehicles.

08:02 EDT Creative Medical Technology announces $2M share repurchase program - Creative Medical Technology announced that its Board of Directors has approved a share repurchase program. The program authorizes the company to repurchase up to $2M of its shares of common stock, in the open market or through privately negotiated transactions, in accordance with applicable securities laws and other restrictions. The program has no termination date, may be suspended or discontinued at any time, and does not obligate the company to acquire any particular number of shares of common stock.

08:01 EDT Valens Semiconductor announces collaboration with iCatch Technology - Valens Semiconductor announced that it is collaborating with Taiwan-based iCatch Technology, a leading Artificial Intelligence image processing IC fabless semiconductor design company, to develop a multi-camera videoconferencing solution that will provide an improved and consistent user experience in-and-across conference rooms. The solution will transform the system architecture of multi-camera videoconferencing applications by seamlessly embedding considerably smaller and lower cost cameras anywhere in a room, while reducing power consumption and costs, producing/delivering the best and most efficient room view coverage.

07:55 EDT GameStop director buys $112K in common stock - In a regulatory filing, GameStop disclosed that its director Lawrence Cheng bought 5K shares of common stock on June 9th in a total transaction size of $112K.

07:48 EDT Draganfly says 'well poised' for BVLOS drone operation regulations - The company said, "Draganfly is well poised to meet the market acceleration of the evolved and newly announced regulations governing Beyond Visual Line of Sight drone operations by the Federal Aviation Administration. Draganfly has been actively preparing for this evolution, ensuring it is well-positioned to be of service to its existing and future public safety-First Responder, Search & Rescue, Wildfire, Medical and Defence customers. As part of this development, the FAA has announced important updates to drone waivers to enhance safety and expand operations. These updates were created through collaborative efforts between public safety stakeholders, companies, and the FAA. The FAA has introduced new waivers and templates that streamline the approval process for drone operations, particularly in the public safety sector. The Drone as a First Responder BVLOS/FR-BVLOS significantly reduces the approval timeframe from over six months to just a few days. This improvement will benefit Draganfly, enabling the Company to expand its presence in multiple industries and capitalize on more opportunities in the public safety sector."

07:45 EDT Crinetics announces inducement grants under Nasdaq listing rule - Crinetics announced that on June 10, 2023, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 331,800 shares of its common stock to 14 new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan. The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $21.67 per share, which is equal to the closing price of Crinetics' common stock on The Nasdaq Global Select Market on June 9, 2023. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Crinetics on such vesting dates. The options are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

07:43 EDT Marimed opens Thrive Wellness Dispensary in Tiffin, Ohio - MariMed opened a Thrive Wellness Dispensary medical dispensary in Tiffin, Ohio, marking the Company's first operational dispensary in the state and the 11th that MariMed owns or manages across five states. The dispensary, the first in Seneca County, a western Ohio county with 54,000 residents, is located at 318 W. Market Street.

07:40 EDT CalciMedica announces relisting on Nasdaq - CalciMedica announced that The Nasdaq Stock Market LLC has approved CalciMedica's application for the relisting of the Company's common stock on the Nasdaq Capital Market. The Company's common stock is expected to commence trading on the Nasdaq Capital Market at the opening of trading on Wednesday, June 14, 2023, under the ticker symbol "CALC". CalciMedica's common stock will continue to trade on the OTCQB until market close on the date before listing on the Nasdaq Stock Market under the ticker symbol "CALC".

07:38 EDT Dragonfly Energy set to join Russell 3000 Index - Dragonfly Energy is set to join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023, according to a preliminary list of additions posted by FTSE Russell.

07:35 EDT Camping World set to acquire Funtime RV in Oregon, no terms - Camping World Holdings announced that it is set to acquire Funtime RV in Oregon. Funtime operates three locations in Tualatin, Sandy, and Klamath Falls, predominantly selling Forest River RV and Keystone RV products. It is anticipated to close in the third quarter of 2023 and will increase the Company's Oregon location count to nine. Marcus Lemonis, Chairman and CEO of Camping World commented, "Funtime RV has been proudly serving Oregon for over 30 years. This acquisition extends our leadership in one of America's largest RV markets and gives us the ability to supercharge our long-standing Wilsonville parts and accessories location with the addition of an excellent RV sales team."

07:35 EDT CTO Realty Growth acquires retail power center in Texas for $61.2M - CTO Realty Growth announced the acquisition of Plaza at Rockwall, a 446,500 square foot multi-tenant retail power center in the Rockwall submarket of Dallas, Texas for a purchase price of $61.2 million. The purchase price represents a going-in cap rate above the range of the Company's current guidance for initial cash yields. Plaza at Rockwall is situated on 42 acres along I-30, just over 20 miles northeast of downtown Dallas, Texas. The Property is 95% occupied and is anchored by Best Buy, Ulta Beauty, Dick's Sporting Goods, JCPenney, Belk, Five Below, and HomeGoods. Plaza at Rockwall is located within one of the wealthiest and fastest growing counties in Texas, benefiting from a five-mile population of nearly 99,000, five-mile average household incomes of more than $142,500, and a five-year projected five-mile population growth rate of 1.25% annually. Following the Company's acquisition of the Property, Dallas-Fort Worth continues to be the Company's second largest market exposure with approximately 18% of the Company's in-place annualized cash base rent coming from the metropolitan statistical area. The Property was purchased using draws from the Company's unsecured revolving credit facility. The acquisition was structured as a reverse like-kind exchange in anticipation of possible future income property dispositions by the Company.

07:34 EDT Auddia launches faidr 3.0 mobile app - Auddia has released faidr 3.0, the new evolution of its Superapp with a vastly different look and feel and new exclusive content offerings. The faidr 3.0 app now offers ad-free AM/FM, podcasts, and many hours of exclusive content including Music Casts, Music Stations, and Discovr, all brought together with a new user interface.

07:31 EDT Endo launches Prevduo pre-filled syringe - Endo International announced that its Par Sterile Products business has begun shipping Prevduo pre-filled syringe, the first and only FDA-approved neostigmine-glycopyrrolate combination product in the U.S.

07:23 EDT Osino Resources announces feasibility study results for Twin Hills - Osino Resources announced the results of the definitive feasibility study for Osino's Twin Hills Gold Project, which is located in central Namibia and is being advanced rapidly through accelerated expansion drilling and fast-tracked development studies. The DFS was prepared by Lycopodium Minerals Canada in accordance with National Instrument 43-101-Standards of Disclosure for Mineral Projects and contemplates a low-risk, technically simple open-pit mine utilizing contract mining and feeding a conventional carbon-in-leach metallurgical plant processing 5mtpa of mineralized material. Heye Daun, Osino's co-founder, President & CEO commented: "We are very pleased with the results of this DFS which confirms Twin Hills as a technically simple, long-life and low-cost gold project with very strong economics and plenty of upside. Now that the DFS has been completed, we will immediately commence with detailed engineering and our vision is to reach a fully financed construction decision by the end of 2023. The results of this DFS demonstrate that Twin Hills is a very robust, cash generative project which will deliver outstanding returns to shareholders once it goes into production, hopefully towards the end of 2025 or early 2026." The Twin Hills Gold Project is located within Namibia's prospective Damara mineral belt. Twin Hills is a sedimentary-hosted, structurally controlled gold deposit that fits the broad orogenic model and is amenable to conventional open-pit gold mining and carbon-in-leach metallurgical processing. Twin Hills lies in proximity to and along strike of the producing, open-pit Navachab and Otjikoto gold mines.

07:20 EDT Jonthan Milner urges Abcam shareholders to elect him as Executive Chairman - Jonathan Milner, the founder and one of the largest investors in Abcam with ownership of 6.3% of the Company, issued an open letter to the Company's shareholders calling for the removal of Peter Allen, Michael Baldock and Sally Crawford as Directors of the Company; and the appointment of Jonathan Milner as a Director of the Company and Executive Chairman. The letter read in part, As the Founder and 6.3% shareholder in Abcam, I am dedicated to helping restore Abcam's financial and operational performance and to driving value for all shareholders. At the Company's upcoming extraordinary general meeting of shareholders scheduled on or before July 18, 2023, you will have an important decision to make regarding the future of your investment in Abcam. Align yourself with me, who has a vested interest in restoring Abcam to the valuation it deserves for the benefit of all Abcam shareholders or stay the course with the current Board, which has lost focus resulting in sustained financial underperformance and value destruction compared to its peers and the broader market. I have attempted to meaningfully engage with Board members on multiple occasions where I offered to help reverse the Company's loss of focus. During that process, I was offered a Board seat subject to restrictions that would impair my ability to hold management accountable and to serve shareholders effectively. It has now been proved that, under the current Chairman, the Board and management team are unable to restore the value of the Company and I feel compelled to return to the Board as Executive Chairman. The persistent erosion of share value in recent years under the current Board signals that the time for change is now. While I am disheartened by Abcam's performance over recent years, I am excited about the Company's future. The global markets that Abcam operates in are robust and growing and the Company continues to serve customers who are loyal and predictable. I believe that management miscues can be easily fixed positioning Abcam to deliver value to shareholders in short, medium and long term. But time is of the essence. If we don't act now, the Company is at risk of passing the point of no return...My expertise and shareholding uniquely make me the only person that can quickly reverse this situation, restore shareholder trust and value and make Abcam the world leading antibody company once again... My six pledges to you: My leadership will re-energize the Board and management team; We will rapidly restore focus around first-rate governance, execution, cost control, transparent investor relations, and executive accountability; We will restore focus on our core competency - being best in the world at antibodies and protein research tools; We will restore focus on costs, to return to strong margins and EPS; We will return to building sustainable shareholder value in the short, medium and long term; I will work tirelessly at the heart of the Company to achieve the above on behalf of all shareholders, employees and customers...For the sake of all stakeholders, I urge shareholders to elect me to the position of Executive Chairman and vote for the proposals outlined below. I can support and constructively challenge the current management team, lead the Board appropriately and increase value for all shareholders. The proposals include: The removal of Peter Allen, Michael Baldock, and Sally Crawford from office as Directors of the Company; The removal of any Director of the Company appointed after the Company's receipt of the request to convene an EGM and before the occurrence of the meeting; The election of Jonathan Milner as a Director and appointment as Executive Chairman of the Board; A shareholder resolution to the Board to conduct a thorough search for candidates and appoint at least two other independent, highly qualified Directors to the Board promptly after the meeting;Company reimbursement of expenses of Jonathan Milner and affiliates incurred in connection with the foregoing matters."

07:15 EDT Mondee closes secondary offering of common stock - Mondee Holdings announced the closing on June 9, 2023 of an underwritten secondary offering of 5,250,000 shares of Mondee's Class A common stock, par value $0.0001 per share, on behalf of certain stockholders at a price of $10.00 per share. The underwriters have a 30-day option to purchase up to an additional 787,500 shares of Common Stock from the Selling Stockholders. The Company did not sell any shares of Common Stock in the Offering and did not receive any proceeds from the Offering. Morgan Stanley acted as lead bookrunning manager and as representative of the underwriters for the Offering. JMP Securities, A Citizens Company, acted as an additional bookrunner for the Offering. Roth Capital Partners and Northland Capital Markets acted as co-managers for the Offering. Cantor Fitzgerald & Co. also acted as financial advisor.

07:13 EDT Bitfarms increases operational hashrate to 5.3 EH/s - Bitfarms reached a new hashrate high of 5.3 EH/s, up 6% from May 31, 2023. "The first tranche of 2,982 MicroBT miners were installed and began hashing last week at our Rio Cuarto farm in Argentina. These miners contributed an additional 290 PH/s driving our hashrate to 5.3 EH/s," said Ben Gagnon, Chief Mining Officer of Bitfarms. "With these new installations, operating capacity increased to 29 MW at Rio Cuarto and to 207 MW company-wide. An additional 3,300 miners are en route to Rio Cuarto and will improve production and energy efficiency at this facilty when installed in July."

07:11 EDT Augmedix establishes AI Advisory Council - Augmedix announced the establishment of an AI Advisory Council. The healthcare industry's adoption of AI is growing very rapidly and Augmedix is committed to harnessing the power of AI thoughtfully and responsibly to provide its customers with solutions they can trust. The Advisory Council will provide advice and guidance to the Augmedix senior leadership team on matters related to the integration of AI into the Company's product development roadmap. The AI Advisory Council will be led by Joe Marks, Ph.D., who has served as a director of the Company since 2020. Previously he was the Executive Director of Carnegie Mellon University's Center for Machine Learning and Health. Members of the council will include distinguished industry thought leaders from computer science, bioinformatics, digital healthcare, as well as Augmedix customers. These individuals will bring diverse expertise and perspectives from academic institutions, corporate entities from various sectors, healthcare industry associations, as well as civil society organizations associated with AI. The council will hold a variety of responsibilities, including discussing regulatory frameworks, evaluating risks and opportunities for ambient medical documentation product development, reviewing AI applications and algorithms, monitoring and addressing ethical concerns, providing strategic advice and engaging with key stakeholders.

07:10 EDT Alvotech & Teva secure AVT04 license date, for proposed Stelara biosimilar - Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries and (TEVA), announced they have reached a settlement and license agreement with Johnson & Johnson ( JNJ) concerning AVT04, Alvotech's proposed biosimilar to Stelara or ustekinumab in the United States. The settlement grants a license entry date for AVT04 in the United States no later than February 21, 2025. "We are delighted to have secured a U.S. license date for our second biosimilar candidate in the U.S. and I believe this exemplifies our multi-product approach to biosimilars globally," said Robert Wessman, Chairman and CEO of Alvotech. "Biosimilars are a key component of Teva's short and long-term strategy," said Sven Dethlefs, PhD, Executive Vice President, North America Commercial at Teva, "Today's announcement is another step forward in our partnership with Alvotech, who shares our commitment to lower the cost burden of biologics on the healthcare system."

07:07 EDT Virtus Investment reports preliminary AUM of $160.9B as of May 31 - Virtus Investment reported preliminary assets under management of $160.9B as of May 31. In addition, the company provided services to $2.6B of other fee-earning assets, which are not included in assets under management.

07:06 EDT Mullen announces development of light-weight EV truck body with Phenix - Mullen Automotive announces development of a light-weight truck body for its Class 3 EV with Phenix Truck Bodies & Van Equipment. Phenix will develop a unique, light-weight body configuration designed to satisfy the needs of Class 3 service body truck fleets, with the goal of offering an EV alternative to ICE vehicles. Upon upfit completion, the Class 3 vehicle will be made available to Phenix commercial fleet customers for evaluation and pilot programs. Pre-production units of the Mullen THREE are available nationally for customer demos and test drives. Fleets, municipalities and small businesses can request a demo of Mullen's commercial vehicles here. Production of the Mullen THREE will take place at Mullen's manufacturing facility in Tunica, Mississippi, with deliveries expected in August and September 2023.

07:05 EDT Apollo infrastructure funds announce structured investment in Yondr Group - Apollo announced that Apollo-managed infrastructure funds have agreed to provide a significant capital commitment to Yondr Group via a structured instrument as the first step in a broader partnership. Proceeds from the investment will be utilized to further Yondr's growth ambitions in support of client demand for its differentiated service proposition as Apollo and Yondr partner to facilitate the continued buildout of Yondr's portfolio of hyperscale data center facilities. In connection with the investment, Apollo Partners Trevor Mills and Andrew Kirby will join Yondr's Board of Directors. Yondr, wholly owned by Cathexis Group, is a leader in developing, owning, and operating build-to-suit hyperscale data centers, primarily in Europe and the Americas. The Company operates a single-tenant, build-to-suit data center strategy, benefitting from key strategic partnerships across the globe which support development and speed to market. Today, Yondr owns and operates a hyperscale data center in the Netherlands, with four additional sites in construction across Europe and the United States expected to come online between 2024 and 2025, all of which are fully contracted with large, investment-grade counterparties. Yondr has advanced plans to continue scaling its portfolio of build-to-suit hyperscale data centers with the support of Apollo to meet the rapidly growing needs of its high-quality customer base, with a continued focus on speed to market, top-tier facility design and performance while leveraging the Company's local expertise.

07:03 EDT Akumin names Krishna Kumar as President and COO - Akumin announced the appointment of Krishna Kumar as President and COO of the company, effective as of June 16. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India.

06:58 EDT AstraZeneca's capivasertib-Faslodex combination granted Priority Review in U.S. - AstraZeneca's New Drug Application, or NDA, for capivasertib in combination with Faslodex has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen, the company announced.

06:51 EDT DigitalBridge announces senior management appointments - The leadership appointments and promotions include: Geoffrey Goldschein, who previously served as Managing Director and General Counsel of DBRG's Investment Management division, has been appointed as Chief Legal Officer and Company Secretary. Francisco Sorrentino has joined DigitalBridge as Chief People Officer. Stephen Stryker has joined DigitalBridge as Chief Information Officer, succeeding Mark Serwinowski, who will be retiring. Justin Chang, who has led DigitalBridge's expansion into the Asia Pacific region as Managing Director, Head of Asia, has been promoted to the role of Senior Managing Director.

06:46 EDT Lazard reports preliminary AUM $230B as of May 31 - Lazard reported that its preliminary assets under management as of May 31 totaled approximately $230B. The month's AUM included foreign exchange depreciation of $2.9B, net outflows of $0.9B and market depreciation of $0.8B.

06:33 EDT Ares Acquisition, X-energy announce update to business combination - X-Energy Reactor Company and Ares Acquisition announced a strategic update to their previously announced business combination agreement that revises the valuation of the transaction. Under the amended terms, X-energy's pre-money equity value has been revised to $1.8B from approximately $2.1B. By establishing a more attractive entry point for investors, X-energy and AAC believe the revised valuation reinforces the long-term value creation opportunity for, and the companies' alignment with, shareholders.

06:21 EDT Nasdaq expects to achieve 35%-38% dividend payout ratio in 3-4 years - Following the Adenza transaction, Nasdaq expects leverage of approximately 4.7x and investment grade ratings of BBB/Baa2 Stable. Nasdaq is committed to reducing leverage to 4.0x in 18 months and to approximately 3.3x in 36 months. Nasdaq intends to pursue its existing capital deployment plan, including steadily increasing its dividend per share and dividend payout ratio to achieve 35%-38% within three to four years. The company intends to repurchase shares over time to partially offset dilution from the transaction in addition to continuing to offset employee share-based compensation.

06:06 EDT Ideaya Biosciences selects monotherapy expansion dose for IDE397 trial - Ideaya Biosciences announced selection of a monotherapy expansion dose for the Phase 2 clinical trial evaluating IDE397 in patients having solid tumors with MTAP deletion. "We have selected a IDE397 Phase 2 monotherapy expansion dose for evaluation in our high-priority solid tumor types with MTAP deletion, including NSCLC, bladder cancer and gastroesophageal cancer. We are in the early stages of enrollment into our global Phase 2 clinical trial monotherapy expansion and have clinical objectives to further define IDE397's monotherapy efficacy in our high priority solid tumor types and to address contribution of components for clinical combinations," said Dr. Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.

06:04 EDT Emeren to sell six rooftop distributed generation projects - Emeren announced that it has entered into an agreement to sell a portfolio of six rooftop distributed generation projects located in Henan province, totaling 29 MW, to CNNP Rich Energ.

06:00 EDT Nasdaq to acquire Adenza from Thoma Bravo for $10.5B in cash and stock

05:46 EDT FleetCor says court order in FTC case limited to injunctive relief - FleetCor Technologies on Friday morning announced that it received the anticipated court order in the Federal Trade Commission marketing practices and disclosure case. The court order limits its injunctive relief to FleetCor's fuel card business in the United States, the company said in a statement. The order requires FleetCorto implement a set of disclosure practices, such as crediting customer payments on receipt date or providing notice to customers in advance of receiving a new fee, it added. The company intends to comply with the order, as required by the court. "We're pleased to close out this chapter of the FTC case," said Ron Clarke, Chairman and CEO of FleetCor. "We remain committed to industry-leading transparency and offering our customers compelling products and services that provide significant value to help them run their businesses."

05:24 EDT Chinook Therapeutics to be acquired by Novartis for $40 per share in cash - Chinook Therapeutics (KDNY) announced that it has entered into an agreement and plan of merger with Novartis (NVS) pursuant to which Novartis will acquire Chinook for $40 per share in cash, or a total of $3.2B. This offer represents a premium of 83% to Chinook's 60-day volume-weighted average stock price and 67% to Chinook's closing price on June 9. In addition, Chinook shareholders will receive contingent value rights providing for payment of up to $4 per share upon the achievement of certain future regulatory milestones with respect to Chinook's lead product candidate, atrasentan. Total consideration including the contingent value right, if the milestones are achieved, would be approximately $3.5B. The transaction has been unanimously approved by the boards of directors of both companies. Completion of the transaction is expected in the second half of 2023, pending approval by Chinook's stockholders and satisfaction of other customary closing conditions. Until that time, Chinook will continue to operate as a separate and independent company. Under the terms of the merger agreement, Novartis will acquire all of the outstanding shares of Chinook through a subsidiary for a price of $40 per share in cash at closing. The CVRs to be issued to Chinook shareholders will provide for payments of up to an additional $4 per share with respect to specific regulatory approvals for atrasentan, $2 of which is related to IgA nephropathy and $2 of which is related to focal segmental glomerulosclerosis. The closing of the proposed transaction is subject to certain conditions, including approval by Chinook's stockholders, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

05:15 EDT Teck Resources comments on engagement for steelmaking coal business - Teck Resources commented on its previously announced engagement with several parties that have submitted unsolicited indications of interest regarding various forms of potential transactions involving Teck's steelmaking coal business. Teck's board of directors and independent special committee are continuing to consider and evaluate all actionable, value-accretive proposals received relating to Teck's steelmaking coal business to determine whether they are in the best interests of Teck's shareholders and all stakeholders. As part of this ongoing review, Teck confirms it is engaging with Glencore around their proposal regarding the steelmaking coal business. The proposal is preliminary in detail, conditional and non-binding. The high degree of interest expressed by a wide range of parties underscores the value of Teck's high-margin, long-life steelmaking coal assets. Teck intends to continue to engage with all parties that have indicated interest to identify a path that realizes value for shareholders while ensuring continued responsible operations in the Elk Valley. There can be no assurance that any transaction will result from the engagement between Teck and the various interested counterparties regarding the steelmaking coal business. Teck does not intend to provide any further updates until it determines that a disclosure is required.

05:05 EDT Autoliv unveils Bernoulli Airbag - Autoliv, unveiled a patented revolutionary new passenger airbag module that is based on Bernoulli's Principle and can inflate larger airbags more efficiently as well as reduce development time and cost. The Bernoulli Airbag will be commercialized during the third quarter and on display at the Autoliv Investor Day today in Auburn Hills, Michigan, USA.